GlassScriptPhysician profile
James Timothy Deppe
NPI 1033110382
$214.32
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.09 | 2019 | |
| Philips North America LLC | $25.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.76 | 2019 | |
| Abbott Laboratories | $21.06 | 2019 | |
| Tandem Diabetes Care, INC. | $20.85 | 2019 | |
| Grifols USA, LLC | $18.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.53 | 2019 | |
| Lilly USA, LLC | $13.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.12 | 2019 | |
| Pulmonx Corporation | $10.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Deppe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.